- Home
- COE vs ADVM Comparison
COE vs ADVM Comparison
Compare COE & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COE
- ADVM
- Stock Information
- Founded
- COE 2011
- ADVM 2006
- Country
- COE Singapore
- ADVM United States
- Employees
- COE N/A
- ADVM N/A
- Industry
- COE Other Consumer Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COE Real Estate
- ADVM Health Care
- Exchange
- COE Nasdaq
- ADVM Nasdaq
- Market Cap
- COE 115.0M
- ADVM 98.0M
- IPO Year
- COE 2016
- ADVM 2014
- Fundamental
- Price
- COE $19.88
- ADVM $4.50
- Analyst Decision
- COE
- ADVM Strong Buy
- Analyst Count
- COE 0
- ADVM 6
- Target Price
- COE N/A
- ADVM $27.83
- AVG Volume (30 Days)
- COE 10.3K
- ADVM 189.1K
- Earning Date
- COE 03-21-2025
- ADVM 03-21-2025
- Dividend Yield
- COE N/A
- ADVM N/A
- EPS Growth
- COE N/A
- ADVM N/A
- EPS
- COE N/A
- ADVM N/A
- Revenue
- COE $41,924,000.00
- ADVM $1,000,000.00
- Revenue This Year
- COE N/A
- ADVM N/A
- Revenue Next Year
- COE N/A
- ADVM $1,162.55
- P/E Ratio
- COE N/A
- ADVM N/A
- Revenue Growth
- COE 69.79
- ADVM N/A
- 52 Week Low
- COE $6.00
- ADVM $3.52
- 52 Week High
- COE $25.70
- ADVM $18.50
- Technical
- Relative Strength Index (RSI)
- COE 52.48
- ADVM 51.62
- Support Level
- COE $18.24
- ADVM $4.20
- Resistance Level
- COE $20.29
- ADVM $4.91
- Average True Range (ATR)
- COE 0.98
- ADVM 0.49
- MACD
- COE 0.13
- ADVM 0.06
- Stochastic Oscillator
- COE 89.28
- ADVM 60.49
Stock Price Comparison Chart: COE vs ADVM
About COE 51Talk Online Education Group
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.